The prevalence of mental disorders is high among pregnant women.[@B01] Major depression during pregnancy is a risk factor for negative outcomes for both mother and child.[@B02] Psychotherapy and pharmacotherapy are well-established conventional treatments for depression. However, some cases fail to respond, and the safety of some psychopharmaceuticals during pregnancy is unclear. Within this context, certain neuromodulation techniques, including repetitive transcranial magnetic stimulation (rTMS), have been studied in pregnant women with depression.

A review of the recent literature[@B03] suggested that rTMS is an effective alternative for the treatment of depression in pregnant women, and there have been no reports of malformations or other relevant negative fetal outcomes.[@B04] However, use of the rTMS technique in pregnant women has only been evaluated in one open study[@B05] and a few case reports; there have been no randomized clinical trials evaluating its use in this setting. Here, we report the cases of four nulliparous pregnant women (one with a twin pregnancy) diagnosed with major depressive disorder and treated with rTMS.

Sociodemographic and clinical features are summarized in [Table 1](#t01){ref-type="table"}. In three patients, rTMS was applied to the left dorsolateral prefrontal cortex (DLPFC) at 3,000 pulses/session (120% of the motor threshold; frequency 10 Hz; figure-eight coil). In the remaining patient, rTMS was applied to the right DLPFC at 1,800 pulses/session (120% of the motor threshold; frequency 1 Hz; figure-eight coil). To evaluate symptoms of depression and anxiety, the 21-item Hamilton Depression Rating Scale (HDRS-21), the 14-item Hamilton Anxiety Rating Scale (HARS-14), and the Clinical Global Impression-Severity (CGI-S) scale were applied before and after rTMS. Three of the patients were medicated, two with sertraline and one with fluoxetine, and the prescribed dosages were maintained throughout rTMS treatment.

According to the HDRS-21 and HARS-14, all patients presented a response, with a 65% mean reduction in depressive and anxiety symptoms. CGI-S scores also showed a 66% reduction in depressive symptoms. All patients tolerated the treatment, although all but one reported some side effects. None of the patients had complications at delivery. All infants had 5-minute Apgar scores of 9, except for the twins born to patient 2, who were preterm (36 weeks) and had Apgar scores of 6 and 8.

Our results are in agreement with existing experience regarding the responses obtained with rTMS in pregnant women with depression. Our choice of the prefrontal cortex as the rTMS target was based on previous reports.[@B05],[@B06] The frequency of stimulation varies according to the side of application. Studies of rTMS in pregnant women with depression have employed 10-25 Hz and 1 Hz in the left and right DLPFC, respectively, quite similar to the frequencies used in the general population of adults with depression.[@B02] Despite these promising findings, there is a need for controlled, double-blind studies involving larger samples, with well-designed rTMS parameters, and even for prospective studies (following pregnant women and their offspring) to assess the long-term safety of rTMS in children exposed *in utero*.
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###### Sociodemographic and clinical features of four pregnant women who received rTMS for major depression, and 5-minute Apgar scores for their children

  Variable                                   Patient 1    Patient 2    Patient 3                 Patient 4   Total sample Mean (SD)
  ------------------------------------------ ------------ ------------ ------------------------- ----------- ------------------------
  Age at rTMS (years)                        38           33           34                        36          35.2 (2.2)
  Week of gestation at symptom onset         4            4            6                         6           5 (1.2)
  Week of gestation at rTMS initiation       4            6            10                        8           7 (2.6)
  Antidepressant use before rTMS (weeks)     52           32           12                        N/A         32 (20)
  Previous major depressive episodes (n)     2            1            1                         1           1.25 (0.5)
  HDRS-21 score                                                                                              
   Before rTMS                               29           27           12                        17          21.2 (8.1)
   After rTMS                                13           4            6                         5           7.0 (4.1)
   Relative change (%)                       -55.2        -85.2        50.0                      -70.6       -65.3 (15.9)
  HARS-14 score                                                                                              
   Before rTMS                               42           15           28                        20          26.3 (11.8)
   After rTMS                                19           3            12                        6           10.0 (7.1)
   Relative change (%)                       -54.8        -80.0        -57.1                     -70.0       -65.5 (11.8)
  CGI-S score                                                                                                
   Before rTMS                               5            6            5                         5           5.3 (0.5)
   After rTMS                                2            1            2                         2           1.8 (0.5)
   Relative change (%)                       -60.0        -83.3        -60.0                     -60.0       -65.8 (11.7)
  Characteristics of rTMS treatment                                                                          
   DLPFC side                                Left         Left         Right                     Left        
   Sessions (n)                              50           38           20                        40          37.0 (12.5)
   Pulses (× 1,000)                          150          114          36                        120         105.0 (48.6)
   % of motor threshold                      120          120          120                       120         
  Concomitant pharmacotherapy                Yes          Yes          Yes                       No          3.0 (75.0)
   Antidepressant                            Sertraline   Sertraline   Fluoxetine                            
   Daily dosage                              150 mg       150 mg       40 mg                                 
  Concomitant psychotherapy                  No           Yes          Yes                       No          2.0 (50.0)
   Technique                                              CBT          PP                                    
   Duration of therapy before rTMS (weeks)                12           36                                    
  Family history of depression               Yes          No           Yes                       Yes         3.0 (75.0)
    Current psychiatric comorbidity          None         OCPD         None                      None        1.0 (25.0)
    Previous psychiatric comorbidity         None         None         Alcohol abuse and BD-II   None        1.0 (25.0)
  Side effects of rTMS                                                                                       
   Pain/discomfort at the application site   No           Yes          Yes                       Yes         3.0 (75.0)
   Transient difficulty in concentration     Yes          No           No                        No          1.0 (25.0)
   Sore throat                               No           No           Yes                       No          1.0 (25.0)

BD-II = bipolar disorder type II; CBT = cognitive behavioral therapy; CGI-S = Clinical Global Impression-Severity; DLPFC = dorsolateral prefrontal cortex; HARS-14 = 14-item Hamilton Anxiety Rating Scale; HDRS-21 = 21-item Hamilton Depression Rating Scale; N/A = not applicable; OCPD = obsessive-compulsive personality disorder; PP = psychodynamic psychotherapy; rTMS = repetitive transcranial magnetic stimulation.
